Can BMS be salvaged?

Quote












anonymous said:
The new KarXT division will save BMS.
Click to expand...
It's going to be the final domino that topples the company IMO.

We overpaid for an asset that has generic competition on the near horizon. $15 billion isn't chump change.

KarXT acquisition is a poorly calculated gamble that has a high chance of failing, although we at least have a couple years until things really start to collapse internally. Do your own due diligence and drink the Kool-Aid at your own risk. Slurp Slurp.
 






anonymous said:
The new KarXT division will save BMS.
Click to expand...
Oh man how many times have we heard this

"Sotyktu will save BMS"

"Zeposia will save BMS"

"Camzyos will save BMS"

"Abecma will save BMS"

etc.. etc... I can go on for days.

KarXT is the proverbial domino that is likely going to topple our company. $15 billion doesn't grow on trees and the margin for error gets thinner by the day.
 












anonymous said:
Oh man how many times have we heard this

"Sotyktu will save BMS"

"Zeposia will save BMS"

"Camzyos will save BMS"

"Abecma will save BMS"

etc.. etc... I can go on for days.

KarXT is the proverbial domino that is likely going to topple our company. $15 billion doesn't grow on trees and the margin for error gets thinner by the day.
Click to expand...
I dont think you understand the talented leadership team that was put in place for KarXT.
 


















anonymous said:
Standing ovation.
Celgene was a one drug company. Celgene came in with no ethics and dominated the naive BMS people. Everyone and their mother in BMS were kissing up to Celgene instead of showing them their place. Happening now as we speak. Unethical org with no brains. That’s Celgene. BMS left its way of working to do all the wrong things the Celgene way. Look at the leftover Celgene. All tight knit and slowly removing BMS people maliciously. All leftover Celgene are unethical and do not follow any BMS regs or SOPs or practically anything. To this day, they don’t consider themselves part of BMS. Rotten bunch.
Click to expand...
Clueless take. BMS ruined Celgene. All near team catalysts were Celgene. BMS brought nothing to the table. If Celgene been able to maintain its independence it would have been incredibly successful. The BMS culture is horrific and its lifers are bloated, inept managers who cannot make any decisions.
 






anonymous said:
Clueless take. BMS ruined Celgene. All near team catalysts were Celgene. BMS brought nothing to the table. If Celgene been able to maintain its independence it would have been incredibly successful. The BMS culture is horrific and its lifers are bloated, inept managers who cannot make any decisions.
Click to expand...
This is the same story for every biotech who got bought out by a big pharma in the last decade or 2. The original biotech leadership from the late 90's and even early 2000's tended to be much more entrepreneurial and clinical. Those guys got the giant stock payouts and left when their companies got bought out. They have been replaced by the usual suspects from the big pharma. These clueless guys just recycle everything they learned from McKinsey and the likes. The results are highly predictable and history simply keeps repeating itself. Anything that big pharma touches turns to you know what. Same old story. Different day.
 






anonymous said:
Clueless take. BMS ruined Celgene. All near team catalysts were Celgene. BMS brought nothing to the table. If Celgene been able to maintain its independence it would have been incredibly successful. The BMS culture is horrific and its lifers are bloated, inept managers who cannot make any decisions.
Click to expand...
The efficacy and safety of the drugs speak for themselves. Show me a drug after Rev, the drugs that BMS invested in with the 70b acquisition. Failed drugs and Delayed launches due to failed Celgene designed trials which were rejected by the FDA. BMS ruined everything by not only keeping tons of ex Celgene but promoting them multiple times. BMS did not show leadership or knowledge and you are seeing the results in massive layoffs.
 






anonymous said:
The efficacy and safety of the drugs speak for themselves. Show me a drug after Rev, the drugs that BMS invested in with the 70b acquisition. Failed drugs and Delayed launches due to failed Celgene designed trials which were rejected by the FDA. BMS ruined everything by not only keeping tons of ex Celgene but promoting them multiple times. BMS did not show leadership or knowledge and you are seeing the results in massive layoffs.
Click to expand...
BMS and its people are dog sh!t. Stop trying to assign blame, we all know BMS is filled with the dregs of humanity
 






anonymous said:
Clueless take. BMS ruined Celgene. All near team catalysts were Celgene. BMS brought nothing to the table. If Celgene been able to maintain its independence it would have been incredibly successful. The BMS culture is horrific and its lifers are bloated, inept managers who cannot make any decisions.
Click to expand...
Hmmm. What I saw from Celgene was a lot of overpaid blowhards who had the same patent cliffs and bought Juno to save themselves. Juno’s labor-intensive, manual model of production was not scaleable commercially. Not to mention that Celgene hadn’t done jack shit about access. Don’t get me wrong… BMS was not the right savior, because it has its head up its ass, but Celgene was already doomed.
 






anonymous said:
Hmmm. What I saw from Celgene was a lot of overpaid blowhards who had the same patent cliffs and bought Juno to save themselves. Juno’s labor-intensive, manual model of production was not scaleable commercially. Not to mention that Celgene hadn’t done jack shit about access. Don’t get me wrong… BMS was not the right savior, because it has its head up its ass, but Celgene was already doomed.
Click to expand...
Bad take. About as bad as us betting on ourselves with deucra and selling apremilast at $2.B a year and growing when Amgen got it. Just because Amgen killed that drug doesn't mean it wouldn't have continued to grow on it's on.
 
























anonymous said:
Not without a new board and c-suite it won’t. Its mind boggling that the largest investors haven’t held a vote of no confidence in both.
Click to expand...
i am on our IR team. the largest investors owning BMS are index funds and quasi-index/passive investors who own it because we're an s&p 500 constituent. that's the majority of the ownership of this company; there is little active ownership to speak of, so naturally no pressure on mgmt. or board to make any substantive changes.

based on convos we've had with investors, the issues at BMS are well known and we're viewed as one of the most dysfunctional and lowest quality companies in pharma. the reason we haven't seen any of these large activist investors step in to shake things up is because the problems are too deeply ingrained and we're perceived as being too far past the point of being able to be fixed. the karuna deal sealed any chance of a turnaround that may have been possible and we now have hedge funds shorting our stock in anticipation of things getting really bad in the next couple years. if/when we get kicked out of the s&p 500, we're completely screwed because all of those passive money flows disappear and there will be very little demand holding up the stock. our $100 billion market cap stock could get cut in half in very short order if that happens.
 












anonymous said:
Now that election results are in, there is hope. Start by dismantling the DEI initiatives.
Click to expand...
Start by make America educated again, make America decent again, make America intelligent again. There will always be DEI because of the make up of this country. Every American needs a job. There will always be immigration as majority of the votes came from those that did not finish college. It is impossible to run this country without the smartness in science, technology, and reason.
 






Top Bottom
Back
Quote